[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"supraventricular-arrhythmia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:supraventricular-arrhythmia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,87],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100427345","rate-rhythm-or-risk-control-for-new-onset-supraventricular-arrhythmia-during-septic-shock-a-randomized-controlled-trial-100427345",false,"NCT04844801","Rate, Rhythm or Risk Control for New-onset Supraventricular Arrhythmia During Septic Shock: a Randomized Controlled Trial","Comparison of Three Care Strategies in Cases of New-onset Supraventricular Arrhythmia During Septic Shock : a Randomized Controlled Trial","CAFS","Inclusion Criteria:\n\n1. Age \\>= 18 years\n2. Septic shock, defined by the association of the following criteria:\n\n   * Documented or suspected infection, with initiation of antibiotic therapy\n   * Initiation of vasopressors (norepinephrine, epinephrine) for at least 1 hour to maintain the MAP \\> 65 mmHg\n3. NOSVA with heart rate ≥ 110 bpm lasting 5 minutes or more\n4. Written informed consent (patient, next of skin or emergency situation)\n5. Affiliation to a social security system\n\nExclusion Criteria :\n\n1. Refractory shock defined by a dose of noradrenaline BASE or adrenaline BASE \\> 1.2 µg\u002Fkg\u002Fmin\n2. Cardiac surgery or cardiac transplant in the previous month\n3. Aortic or mitral mechanical prosthesis, significant mitral stenosis (mitral surface \\\u003C 1.5 cm2)\n4. Congenital heart disease other than bicuspid aortic valve, atrial defect or patent foramen ovale.\n5. History of supraventricular arrhythmia prior to the episode of septic shock defined by a permanent TRSVN or paroxysmal TRSVN requiring long-term specific treatment (heart rate reducer and\u002For antiarrhythmic and\u002For curative anticoagulation) or permanent NOSVA.\n6. NOSVA that began more than 48 hours ago \\* (or more than 24 hours ago under vasopressor). \\* In cases of TRSVN dating back more than 48 hours, the patient may be included after undergoing a transesophageal echocardiogram (only in patients who are intubated and on mechanical ventilation) to rule out the presence of an intracardiac thrombus, coupled with the initiation of curative anticoagulation (in the absence of contraindications contraindication) starting from the transesophageal echocardiography.\n7. Electrical cardioversion or use of amiodarone, other antiarrhythmic, or drug inducing bradycardia (beta-blockers, bradycardic calcium channel blocker, digitalis, flécaïnamide) in the previous 6 hours before inclusion\n8. Contraindication to amiodarone: history of serious adverse event related to amiodarone, history of lung disease related to amiodarone, history of hyperthyroidism related to amiodarone, PR interval \\> 240 ms, severe sinus node dysfunction with no pacemaker, 2°\u002F 3° atrioventricular block with no pacemaker, QTc\\>480 ms, known or treated hyperthyroidism, hypersensitivity to iodine, amiodarone or to any of the excipients, severe hepatocellular insufficiency (prothrombin rate \\\u003C20%), diffuse Interstitial Lung Disease.\n9. Kalemia \\\u003C 3 mmol\u002FL\n10. Pregnant or breast feeding women\n11. Moribund patient or death expected from underlying disease during the current admission; Patient deprived of liberty and persons subject to institutional psychiatric care\n12. Participation to another interventional trial on septic shock and\u002For arrhythmic disease","ALL","18 Years",{"count":20,"type":21},240,"ESTIMATED","INTERVENTIONAL",[24],"NA","New-onset supraventricular arrhythmia (NOSVA) is reported in 40 % of patients with septic shock and is associated with hemodynamic alterations and mortality. The lack of consensus regarding best practices for the management of NOSVA in this setting has led to major variations in practice patterns. Observational studies reported three usual strategies: (i) heart rate control (hereafter rate control) with the use of antiarrhythmic drugs, essentially based on low dose of amiodarone, (ii) rhythm control with the use of antiarrhythmic drugs, essentially based on high dose of amiodarone, and electrical cardioversionand (iii) modifiable NOSVA risk factors control (hereafter risk control) without using antiarrhythmic drugs.\n\nRisk control would minimize adverse events of antiarrhythmic drugs. Rhythm control would rapidly improve haemodynamics via restoring diastole and decreasing cardiac metabolic demand, while minimizing exposure to anticoagulation. Heart-Rate control, would limit potential adverse events of high dose of amiodarone and of electrical cardioversion (only in patients intubated on mechanical ventilation), while controlling haemodynamics. Therefore, it seems important to compare these three strategies.\n\nOur hypothesis is dual: first, that heart-rate control and rhythm control each improve hemodynamics with in fine a decreased mortality, as compared to a risk control; second, that rhythm control outperforms rate control in this setting.\n\nThis is a multicenter, parallel-group, open-label, randomized controlled superiority trial to compare the effectiveness and safety of these three strategies (risk control, rate control and rhythm control) for NOSVA during septic shock.",[27,28],"Supraventricular Arrhythmia","Septic Shock",[30,31,32,33,34,35],"New-onset supraventricular arrhythmia","Atrial fibrillation","Septic shock","Critically ill patient","Strategies","Antiarrhythmic drugs","RECRUITING","2026-01-05",{"date":39,"type":40},"2026-01-07","ACTUAL",{"date":42,"type":40},"2021-11-09",{"date":44,"type":21},"2026-03",{"name":46,"class":47},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":48},"100488678","implanted-loop-recorders-for-detection-and-management-of-arrhythmia-with-bruton-tyrosine-kinase-inhibitors-100488678","NCT05643235","Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors","Implanted Loop Recorders (ILR) for the Detection and Management of Arrhythmia in Patients Treated With Bruton Tyrosine Kinase (BTK) Inhibitors","Inclusion Criteria:\n\n* \\>18yo\n* Willing to sign and date consent form,\n* Willing to be remotely monitored\n* Initiating BTK inhibitor for approved condition (i.e. CLL, Waldenstrom's, etc)\n* Willing to have Medtronic cardiac monitor inserted to allow at minimum 24 hours continuous monitoring prior to initiating BTK inhibitor\n\nExclusion Criteria:\n\n* Documented AF\u002FVA in past 12 months\n* Cerebral Vascular Accident (CVA) or Transient Ischemic Attack (TIA) in past year\n* Has current implanted pulse generator, defibrillator, pacemaker, or resynchronization device\n* heart surgery within past 90 days\n* Myocardial Infarction within past 90 days\n* Patient is taking an anti-arrhythmic or anticoagulant\n* has concomitant condition that precludes safe participation in study (substance abuse, etc)\n* Enrollment in separate study that could confound results of this study",{"count":57,"type":21},50,[24],"This study will enroll patients initiating Bruton Tyrosine Kinase (BTK) inhibitors without history of documented arrhythmia while on therapy using the Medtronic LINQ-2 insertable cardiac monitor (ILR). The incidence of new onset atrial fibrillation (AF) and other arrhythmia will be determined. Actions taken in response to device detected arrhythmia will be recorded.",[61,27,62,63,64],"Atrial Fibrillation","Ventricular Arrhythmias and Cardiac Arrest","Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",[66,67,68,69,70,71,72,73,74,75,76,77],"Bruton tyrosine kinase (BTK)","Chronic Lymphocytic Leukemia (CLL)","Mantle Cell Lymphoma","Waldenstrom's macroglobulinemia","atrial fibrillation (AF)","ventricular arrhythmia (VA)","sudden cardiac death","ibrutinib","acalabrutinib","zanubrutinib","pirtobrutinib","Implanted Loop Recorder\u002FImplanted Cardiac Monitor (ILR)","2025-09-12",{"date":80,"type":40},"2025-09-18",{"date":82,"type":40},"2023-01-01",{"date":84,"type":21},"2030-12-01",{"name":86,"class":47},"Northwell Health",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":98,"conditions":99,"keywords":100,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":48},"100520788","non-invasive-differentiation-of-supraventricular-tachyarrhythmia-100520788","NCT06061120","Non-invasive Differentiation of Supraventricular Tachyarrhythmia","Non-invasive Differentiation of Supraventricular Tachyarrhythmias by Questionnaire and High-resolution ECG in the Context of Ablation Treatment","NIDSA","Inclusion Criteria:\n\n* Scheduled for ablation of a supraventricular tachycardia (atrial fibrillation, typical atrial flutter, AV nodal reentry tachycardia, accessory pathway)\n* majority\n\nExclusion Criteria:\n\n* Unstable patient with need for intensive medical care\n* Lack of language skills or limited cognitive abilities that prevent a differentiated anamnesis and information.\n\nExclusion criteria for study section Questionnaire:\n\n\\- Competing clinically present arrhythmias, including relevant supra- and ventricular extrasystole (\\>5%\u002Fdie).\n\nExclusion criteria for study section Extended high-resolution ECG:\n\n* Previous electrophysiological ablation at the same site for atrial fibrillation.\n* Relevant supra- and ventricular extrasystole (\\>5%\u002Fdie).\n* Other clinically present arrhythmias are not excluded if they can be sequentially triggered and ablated (e.g. atrial fibrillation and atrial flutter). Since separate detection is possible with the high-resolution ECG.\n* Implanted active electrical device (e.g. pacemaker, defibrillator, deep brain pacemaker)\n* Allergy to measuring electrodes",{"count":96,"type":21},1250,"OBSERVATIONAL","1. Questionnaire for supraventricular tachycardia: About history and targeted diagnosis of supraventricular tachycardia\n2. Extended Signal-averaged ECG for detailed P-Wave analysis and to calculate a virtual atrial electrocardiogram (ECG)",[27,61],[101,102,103,27,61],"Electrocardiogram","Signal-averaged P-Wave","Questionnaire","2023-09-24",{"date":106,"type":40},"2023-09-29",{"date":108,"type":40},"2021-09-01",{"date":110,"type":21},"2026-09-30",{"name":112,"class":47},"RWTH Aachen University"]